Navigation Links
ThromboGenics NV Announces Business Update and Half Year Results 2009
Date:8/27/2009

r the symbol THR. More information is available at www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

    For further information please contact:

    ThromboGenics
    Dr. Patrik De Haes, CEO
    Tel: +32-16-75-13-10
    patrik.dehaes@thrombogenics.com

    Chris Buyse, CFO
    Tel: +32-16-75-13-10
    chris.buyse@thrombogenics.com

    Citigate Dewe Rogerson
    Amber Bielecka/ David Dible/ Nina Enegren
    Tel: +44(0)207-638-95-71
    amber.bielecka@citigatedr.co.uk

'/>"/>
SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ThromboGenics NV: Business Update
2. ThromboGenics Announces Business Update and 2008 Full Year Results
3. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
4. ThromboGenics N.V.: Business Update
5. ThromboGenics Announces Half Year Results 2008
6. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
7. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
8. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
9. ThromboGenics N.V. - Business Update
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. ThromboGenics Announces 2007 Full Year Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...November 24 Shire plc (L...opharmaceutical company, today,announced that it h...y for,velaglucerase alfa, the company,s enzyme rep...of Type 1 Gaucher disease. This is the third marke...een submitted, with previous,submissions in the Un...
(Date:11/24/2009)...Y, Calif., Nov. 24 Genom...hat Randy Scott, Genomic Health,s Executive Chairm...Health Care Conference in New York City on Tuesday...ess the live and subsequently archived webcast of ...tion of Genomic Health,s website at http://invest...
(Date:11/24/2009)... Program Connects Customers with Partners Validate...A Genotek Products , Otta... a leading provider of products for biological sam...ay announced its new global partner program. The p...otek,s partner community and is designed to help p...
(Date:11/24/2009)...Nov. 24 Cell Therapeutic...ll present at the 21st Annual Piper Jaffray Health...mber 1-2, 2009, at the New York Palace Hotel. ,...00 a.m. Eastern Time in Holmes 1 (4th Floor). A li...ilable at www.celltherapeutics.com , and it will ...
Breaking Biology Technology:Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4Genomic Health to Present at Piper Jaffray Health Care Conference 2DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3
...oved by the Fda For Hypotrichosis of,Eyelashes , ... approved LATISSE(TM),(bimatoprost ophthalmic solu... of the eyelashes. Eyelash hypotrichosis is anothe...es. LATISSE(TM) is the first and only,FDA-approved...nence as,measured by increases in length, thicknes...
... Southern California (USC) have, for the first tim...) cells from rats. This breakthrough finding will ...mal models for the study of a range of human disea.... 26 issue of the journal Cell . , "This is a m...know that rats are much more closely related to hu...
...stem against deadly bacteria. However, how the ste... body is not yet known. To date, B. Pseudomallei,... to elude medics. It can remain hidden in the huma...e immune system. The bacteria can suddenly become ...g in the patient dying from blood poisoning. AMC p...
Other Biology Technology:MultiVu Video Feed: U.S Food and Drug Administration (Fda) Approves Latisse(TM) -- 2MultiVu Video Feed: U.S Food and Drug Administration (Fda) Approves Latisse(TM) -- 3USC researchers derive first embryonic stem cells from rats 2USC researchers derive first embryonic stem cells from rats 3
(Date:11/24/2009)...d flabby arteries from collapsing have been true l... no longer needed -- once the arteries are strengt...s had no choice but to leave them in place. , Pr...rtment of Biomedical Engineering has developed a n...s where they,re needed, then dissolves. , "Our n...
(Date:11/24/2009)...is a matter of debate. A high-profile study a few ...t of their carbon from trees and leaves, evidence ...aquatic ecosystems. , But new research from the ...to be true. Algae provide a much richer diet for f...published this week in the Proceedings of the Nat...
(Date:11/23/2009)...er 23, 2009 Applied mathematicians dissected the ... ), a characteristic long leaf with a saddle-like ...e edges. The simple cause of the lily,s fan-like s...ng differential growthwas revealed by using an equ... Haiyi Liang, a postdoctoral student at Harvard,s...
Breaking Biology News(10 mins):A coating for life 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3The cause behind the characteristic shape of a long leaf revealed 2Lexington International LLC Receives 2009 U S Presidents E Award Recognizing its Export Achievements 6381 1Lexington International LLC Receives 2009 U S Presidents E Award Recognizing its Export Achievements 6381 2Lexington International LLC Receives 2009 U S Presidents E Award Recognizing its Export Achievements 6381 3Zydena is Efficacious in Once Daily Dosing for Erectile Dysfunction Positive BPH Results 6378 1Zydena is Efficacious in Once Daily Dosing for Erectile Dysfunction Positive BPH Results 6378 2Zydena is Efficacious in Once Daily Dosing for Erectile Dysfunction Positive BPH Results 6378 3Drug for erectile dysfunction improves heart function in young heart disease patients 61624 1
...d gene therapy in two separate studies to renew br...and rats with a drug-induced form of Parkinson,s d...ientific publications Brain and The Journal of Neu...alt Parkinson,s disease at its onset and another s... occur when treating the disease in its later stag...
...y in St. Louis has proposed that evolution is the ...ment rather than physical processes, such as plate...iversity assistant professor of geomicrobiology in...in Arts & Sciences, studying Cyanobacteria ?ba...o produce oxygen and biomass ?has concluded that t...
...arolinska Institutet announced today that they hav...prove healthcare by accelerating the translation o...gnosis, prognosis, and treatment. , During the ne...s and measurement of gene expression in patients w...hritis, asthma and dyslexia. These diseases affect...
Other Biology News:Gene therapy for Parkinson's disease moves forward in animals 2Gene therapy for Parkinson's disease moves forward in animals 3Gene therapy for Parkinson's disease moves forward in animals 4Family trees of ancient bacteria reveal evolutionary moves 2Family trees of ancient bacteria reveal evolutionary moves 3Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance 2Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance 3
Mouse Anti-Human Troponin I Monoclonal Antibody, Unconjugated, Clone 22B11 from Santa Cruz Biotechnology, Inc.
... freezers , Ultima II Series ,Developed ...represents the finest, most enhanced ultra-low fre...ood bank configurations, each Ultima II freezer in...system with built-in voltage boost and surge suppr...
Perfusion Pressure Kit - 8 channel from AutoMate Scientific, Inc
BspT107 I (HgiC I, Ban I) from Takara Mirus Bio
Biology Products: